In advanced NSCLC, a PD-L1 TPS ≥ 50% indicates a likely response to anti-PD-1/PD-L1 therapy, negating the need for cytotoxic combination and its associated toxicities [1]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.